TABLE 1

Comparison Between SUVmax and Blood Flow in the Patient and Clinical and Tumor Characteristics

SUVmaxBlood flow (mL/min/g)
VariableParameternMedianInterquartile rangePMedianInterquartile rangeP
MenopausalNo22 (55%)6.75.2–9.90.480.310.23–0.380.72
Yes18 (45%)6.85.0–14.50.320.20–0.43
Tumor size<5 cm24 (60%)6.85.3–10.20.500.330.21–0.380.29
≥5 cm16 (40%)7.95.0–13.30.310.22–0.47
Lymph node involvementNo13 (32%)5.43.9–13.00.540.280.20–0.390.40
Yes27 (68%)7.95.5–11.70.330.23–0.42
Histologic grade1/226 (65%)5.64.0–8.1<0.0010.270.20–0.370.030
314 (35%)13.38.5–16.30.390.32–0.46
ER14 (35%)10.36.8–12.90.080.290.20–0.430.86
+26 (65%)6.14.6–8.90.320.23–0.40
PR19 (48%)9.26.5–12.70.0210.360.25–0.420.18
+21 (52%)5.53.1–9.30.280.20–0.38
HER225 (63%)9.34.5–13.00.600.280.20–0.450.64
+15 (37%)6.55.5–8.10.330.27–0.38
TNNon-TN30 (75%)6.45.1–9.00.0420.320.23–0.390.82
TN10 (25%)11.910.2–14.20.230.18–0.45
Lymphovascular invasionNo6 (15%)6.95.3–11.20.650.320.21–0.380.91
Yes34 (85%)5.43.6–12.10.280.22–0.41
Ki67 score≤median23 (58%)5.73.5–7.0<0.0010.280.19–0.370.09
>median17 (42%)12.17.9–14.60.380.25–0.45
CD34 score≤median20 (50%)7.74.6–12.60.570.240.17–0.380.027
>median20 (50%)6.65.4–10.70.360.26–0.46
CD105 score≤median20 (50%)6.13.7–12.60.310.230.17–0.320.002
>median20 (50%)7.56.4–11.90.370.32–0.44